Innovative Fc Fusion Technology Clears European Regulatory Hurdles

The European Medicines Agency (EMA) granted marketing authorization for Alprolix (eftrenonacog alfa), a Hemophilia B treatment co-developed by Biogen (BIIB) and Swedish Orphan Biovitrum (Sobi, STO: SOBI), on May 12, 2016. This approval establishes a regulatory framework for Alprolix to be marketed throughout the European Union (EU), signaling the arrival of a new drug that significantly improves the convenience of administration compared to existing standard treatments. Alprolix, which utilizes Fc fusion protein technology to achieve extended half-life, is considered an innovative treatment option that can dramatically improve the quality of life for patients by reducing the frequency of injections.

Clinical Efficacy Demonstrated Through Global Phase 3 Trials

The EMA approval of Alprolix is based on robust data from the 'B-LONG' Phase 3 study, which involved adult and adolescent patients with prior treatment experience, and the 'Kids B-LONG' study, which included children under 12 years of age. Clinical results demonstrated that Alprolix, when administered prophylactically, effectively prevents and controls bleeding with only one injection per week or every 10-14 days, addressing the frequent dosing burden associated with existing products. Given that the regulatory agency has officially recognized the drug's excellent safety profile and efficacy through rigorous review, it is expected that healthcare professionals in Europe will actively change their prescribing practices.

Commercialization Rights Transfer to Accelerate Market Penetration in Europe

According to the co-development agreement between Biogen and Sobi, the marketing authorization for Alprolix in Europe was officially transferred to Sobi in October 2016, following the European Commission's approval. Consequently, Sobi will be responsible for commercialization in Europe, Russia, parts of North Africa, and the Middle East, while Biogen will handle sales in North America and other global regions. Sobi already possesses a strong rare disease network throughout Europe, enabling rapid distribution; however, it faces the practical challenge of quickly completing price negotiations with national health authorities and securing reimbursement listings after marketing authorization.

Intensified Competition in the Next-Generation Extended Half-Life (EHL) Treatment Market

With Alprolix's entry into the European market, fierce competition with CSL Behring's Idelvion, which also received EMA and U.S. FDA approval in 2016, is inevitable. The market, previously dominated by Pfizer's BeneFIX and other standard half-life products, is rapidly being reshaped, and pharmaceutical companies must shift from simply supplying blood products to a competitive landscape focused on patient convenience. Biogen aims to solidify its market dominance by rapidly increasing Alprolix's market share in Europe, building on its global sales of USD 334 million in 2016.